101¦~1¤ë¸¹ ¹D ªk ªk °T (237) |
DEEP & FAR |
|
¥¦æ¿é¤Jªñªp |
§d¥©¬Â µ{§Ç¤@²Õ°Æ¥D¥ô ¡D¬Fªv¤j¾Çªk«ß¾Ç¨t¾Ç¤h |
|
|
||
¼w°êªk°|¤w¸g°ò©ó®t¤£¦h¬Û¦P¨Æ¹ê¦Ó»{©w¡A°Ó«~³Q¸m©ó¶R¤è¦³³B¸mÅv¤Oªº¥«³õ¤W¡C(Glaxo v. Kohlpharma, ªk°|»{¬°¥»®×ªº©Ò¦³¨Æ¹êµLªkÂç²M¥B¨ã¦³°ª«×¼vÅT¤O¡C¦]¦¹ªk°|»é¦^§Y¨Mµô§P¨Ã©R¥O¼f²z¸Ó®×¡Cªk°|°û©Ú¤F°Ñ¦Ò´£¥æ§Y±N¹ï©óPeak Holding v. Axolin-ElinorÅ¥ÃÒªº¼Ú¬wªk°|¡A¸Ó®×«Y¥Ñ·ç¨å¤W¶Dªk°|©Ò´£¥æ¡A¥H¼á²M¦p¤U¥ß³õ¡G¦p¦³¤@µ§©óEEA°Ï°ìªº¾P°â¡A¦ý«´¬ù¨î¤£±o©ó·í¦a³c°â¡C µû½× ¦bBoehringer®×¤¤¡AJacobªk©x¹ï©ó¨º¨Ç¤¹³\¯u«~¦A¥]¸Ë¤§¶i¤f°Ó³Q±±½Ñ°Ó¼Ð«IÅvªº¤@¯ëì«h·P¨ì»´½°¡C¥Lª`·N¨ì¡u¦³®É§Ú«ä¦ÒµÛªk«ß¤]³\¦b¦¹»â°ì¥¢¥h¯u¹êªº·Pı¡X²¦³º¡A§Ú̶ȦҶq¦b§¹¬üª¬ºA¤U¡AÅý¨ä°Ó«~¨Ï¥Î©Ò¦³¤Hªº°Ó¼Ð¡C§Ú»{¬°ªk³W©Ò³´¤Jªº§x¹Ò·|¥O¤@¯ë®ø¶OªÌ·P¨ì¦YÅå¡v¡C ¦bªk°|ªºÆ[ÂI¤¤¡A¥u¦³·íºc¦¨¤£¤½¥Ävª§®É¡A¥¦æ¿é¤J¤~¸û¤Þ°_¤Ï¹ï¡A¦Ó¥B¦³Ãö¥éŧªº²{¦sªk³W¡A´N¨äÆ[ÂI¡A«Y¾A©ó³B²z³o¨Ç®×¥ó¡C¦Ó¨Ï¥Î°Ó¼Ðªk³B²z³o¨ÇijÃD¡A¯A¤Î§ó¶i¤@¨B©µ¦ù쥻ªº¨î©wªk¥ß·N¡A¥H±N¥¦æ¿é¤JªÌ¯Ç¤J°Ó¼Ð«IÅvªº·§©À¤¤¡C¦Ó³oÓ©µ¦ù³y¦¨³oÓijÃD¿ùºî½ÆÂø¡A¨Ã¤w¢¨Ï¨ä¶·n§ó¦h¼Ú¬wªk°|¤w¸g¾Ú¥H«ü¾Éªº°Ñ¦Ò¡C^°êªk°|©óBoehringer¤ÎGlaxo¨â®×¤¤¡Aªí¥Ü¥X¯u¹ê¤£±¡Ä@¤¶¤J¼Ú¬wªk°|¡]ÁöµM¦bBoehringer¤@®×¤¤¡A¥¦³Ì²×¦P·N³o¼Ë°µ¡^¡C ³o¨Ç®×¨ÒÅã¥Ü¥X§Ú̶Z¥¦æ¿é¤JªÌ¥i¥H©ÎªÌ¤£¥i¥H°w¹ïì¥]¸Ë¶i¦æ¦óºØ¦A¥]¸Ëªº©ú½T¬É½u¡A¤´µM¦³¨Ç¶ZÂ÷¡C¾¨ºÞ¦p¦¹¡Aªk°|¹ï©ó¬O§_¦A¸Ë½c¬Û¹ï©ó¦A¼ÐÅÒ©óÃÄ«~»â°ì¤¤¬O«ÈÆ[¥²nªºÆ[ÂI¡A¬O¨ü¨ìÅwªïªº¡C±qªk°|°ò©ó¨Æ¹êªº¤è¦¡Åã¥Ü¥X¡A¦b¨ä¥L°Ó«~I´º¤U«Ü¥i¯àÀò¦Ü¤£¦Pªºµ²ªG¡AµM¦Ó¡A¤j²³¹ï©ó¥]»q¤W¥~¤å¼ÐÅÒªºµJ¼{µ{«×¥i¯à·|´î¤Ö¨Ç¡C --- ²Ä7±ø(ì¤å) Exhaustion of the rights conferred by a Trade Mark¡]±Â¤©°Ó¼ÐÅv§Q¤§¯ÓºÉ¡^ 1. The trade mark shall not entitle the proprietor
to prohibit its use in relation to goods which have been put on the market in
the Community under that trade mark by the proprietor or with his consent. |
||